Last checked at 8 May 2017 15:02
e-Therapeutics plc
('e-Therapeutics' or the 'Company')
Notice of Annual General Meeting and Annual Report
Oxford, UK, 8 May 2017 - e-Therapeutics plc (AIM: ETX) announces that its annual report and accounts for the year ended 31 January 2017, which includes the notice convening the Company's 2017 Annual General Meeting (AGM), has been posted to shareholders today.
An electronic copy of the annual report can be downloaded from the Company's website at www.etherapeutics.co.uk/investors/financial-reports
The 2017 AGM will take place at 11:00 am on 31 May 2017 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH.
-Ends-
Contacts:
e-Therapeutics plc Ray Barlow, CEO Steve Medlicott, Finance Director
| Tel: +44 (0) 1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Michael Meade / Freddie Barnfield (Nominated Adviser) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
Instinctif Partners Melanie Toyne Sewell / Alex Shaw | Tel: +44 (0) 207 457 2020 Email: e-therapeutics@instinctif.com |
About e-Therapeutics plc
e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.
The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.
e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.